MetaCap

Gyre Therapeutics (GYRE) vs Kamada (KMDA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Kamada (KMDA) has outperformed Gyre Therapeutics (GYRE) over the past year, gaining 14.7% versus a loss of 44.2%. Over five years, KMDA leads with a +22.7% price change compared with -77.5% for GYRE. Gyre Therapeutics is the larger company by market cap ($460.8 million vs $446.8 million), about 1.0 times the size, while Kamada is growing revenue faster (+12.1% vs +10.2%).

On valuation, Kamada trades at a lower forward P/E (13.3x vs 70.2x for Gyre Therapeutics). Kamada pays a dividend yielding 7.24%, while Gyre Therapeutics does not currently pay one. Kamada converts more of its revenue into profit, with a net margin of 11.2% versus 8.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GYRE-44.24%KMDA+14.67%
+42%-4%-51%
Nov 21, 20251 yearNov 20, 2026
GYRE-78.58%KMDA+38.21%
+65%-13%-92%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GYRE versus KMDA key metrics
MetricGYREKMDA
Share price$4.21$7.74
Market cap$460.79M$446.85M
1-day change-6.86%-1.15%
YTD return-40.37%+9.63%
1-year return-44.24%+14.67%
5-year return-77.55%+22.66%
P/E ratio (TTM)—20.37
Forward P/E70.1713.34
EPS (TTM)$-0.31$0.38
Dividend yield0.00%7.24%
Annual dividend$0.00$0.56
Revenue (latest FY)$116.59M$180.46M
Revenue growth (YoY)+10.24%+12.12%
Net income (latest FY)$9.88M$20.20M
Gross margin95.35%42.34%
Operating margin9.85%14.54%
Net margin8.47%11.19%
52-week high$9.14$9.35
52-week low$3.97$6.63
Distance from 52-week high-53.94%-17.22%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+343.47%+77.65%
Average volume181.04K121.87K
Shares outstanding109.45M57.73M
Employees625462
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • KMDA has outperformed GYRE by 58.9 percentage points over the past year.
  • Kamada offers a meaningfully higher dividend yield (7.24% vs 0.00%).

About Gyre Therapeutics

GYRE stock →

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis.

Health Care · Biotechnology: Pharmaceutical Preparations · 625 employees

About Kamada

KMDA stock →

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics.

Health Care · Biotechnology: Pharmaceutical Preparations · 462 employees

GYRE vs KMDA FAQ

Which is bigger, Gyre Therapeutics or Kamada?

Gyre Therapeutics (GYRE) is larger, with a market capitalization of $460.79M compared with $446.85M for Kamada (KMDA).

Which stock has performed better over the past year, GYRE or KMDA?

KMDA returned +14.67% over the past 12 months, compared with -44.24% for GYRE (price return, excluding dividends). Past performance does not predict future results.

Which pays a higher dividend, Gyre Therapeutics or Kamada?

Kamada pays a dividend yielding 7.24%, while Gyre Therapeutics does not currently pay a regular dividend.

Are Gyre Therapeutics and Kamada in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons